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Xanthohumol (XN), a simple prenylated chalcone, can be isolated from hops and
has the potential to be a cancer chemopreventive agent against several human
tumor cell lines. We previously identified valosin-containing protein (VCP) as a
target of XN; VCP can also play crucial roles in cancer progression and prognosis.
Therefore, we investigated the molecular mechanisms governing the contribution
of VCP to the antitumor activity of XN. Several human tumor cell lines were trea-
ted with XN to investigate which human tumor cell lines are sensitive to XN. Sev-
eral cell lines exhibited high sensitivity to XN both in vitro and in vivo. shRNA
screening and bioinformatics analysis identified that the inhibition of the adeny-
late cyclase (AC) pathway synergistically facilitated apoptosis induced by VCP
inhibition. These results suggest that there is crosstalk between the AC pathway
and VCP function, and targeting both VCP and the AC pathway is a potential
chemotherapeutic strategy for a subset of tumor cells.
X anthohumol (XN) is a prenylated chalcone present in hops(Humulus lupus L.) and beer.(1) XN has received much
attention in the last two decades, including reports of its vari-
ous biological properties, such as anti-inflammatory,(2) anti-
oxidant,(3) anti-angiogenic(4) and antibacterial effects.(5) Fur-
thermore, XN harbors anti-tumorigenic effects toward different
types of cancer cells(6) via intracellular reactive oxygen species
(ROS) induction,(7) NF-jB and Akt inhibition,(4,8) endoplasmic
reticulum (ER) stress induction(9) and disruption of the BIG3-
PHB2 interaction.(10)
We previously reported that XN binds directly to valosin-
containing protein (VCP) and modulates autophagy by inhibit-
ing VCP functions.(11) VCP, also known as p97, belongs to the
ATPase associated with diverse cellular activities (AAA)
ATPase family and has a wide variety of cellular functions,
such as autophagosome maturation,(12,13) endoplasmic reticu-
lum-associated degradation (ERAD)(14) and the enhancement
of NF-jB signaling.(15,16) Therefore, our finding that XN mod-
ulated the function of VCP may explain how XN exhibited the
abovementioned biological effects, such as autophagosome
maturation, ER stress induction and NF-jB inhibition. In addi-
tion, because clinical studies have identified a correlation
among elevated VCP expression and the progression, prognosis
and metastatic potential of gastric carcinoma,(17) pancreatic
ductal adenocarcinoma(18) and prostate cancer,(19) the antitu-
mor effects of XN can be attributed to the inhibition of VCP
function. However, the molecular mechanisms governing the
contribution of VCP to the antitumor activity of XN have
remained elusive.
In this study, we performed genome-wide shRNA screening
and identified the adenylate cyclase (AC) pathway as genes
relating to the antitumor activity of XN against human tumor
cells. This pathway regulates various cellular functions via
activating PKA-dependent phosphorylation.(20) However, there
are no reports that show the relevance of AC/PKA pathway
inhibition to the antitumor activity of XN targeting VCP.
Material and Methods
Compounds. H-89 was purchased from Cayman Chemical
(Ann Arbor, MI, USA). Paclitaxel (PTX) was purchased from
Wako Pure Chemical Industries (Osaka, Japan). KT5720 was
purchased from Tocris Bioscience (Bristol, UK). Eeyarestatin I
(ESI) was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA).
Isolation of xanthohumol from hops. Xanthohumol was iso-
lated and purified from Xantho-Flav Pure (Hopsteiner, Ger-
many). The extract was purified by using HPLC (UG 80,
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20 mm, 250 mm; Shiseido, Tokyo, Japan) with 70% aqueous
MeOH to obtain pure XN as previously described.(11)
Cell lines. Human epidermoid carcinoma A431 cells, human
esophageal cancer EC17 cells and human prostate cancer PC-3
cells were provided by M. Kawada (Institute of Microbial
Chemistry, Japan). Human esophageal cancer EC109 cells
were provided by Columbia University (New York, NY,
USA). Human cervical cancer HeLa cells were provided by M.
Yoshida (RIKEN, Japan). Human embryonic kidney HEK293T
cells were provided by S. Saiki (Juntendo University, Japan).
Human colorectal tumor LoVo, HT29, Colo-201, HCT116,
LS-174T, SW620, DLD-1, SW48 and SW480 cells, human
lung cancer A549 cells, human breast cancer MCF-7 cells, and
human melanoma A2058 cells were obtained from the Ameri-
can Type Culture Collection (ATCC, Rockville, MD, USA).
A431 cells were maintained in DMEM supplemented with 5%
calf serum (CS), 100 U/mL penicillin G (Sigma-Aldrich, St.
Louis, MO, USA), and 0.1 mg/mL kanamycin (Sigma-Aldrich)
at 37°C in a humidified atmosphere containing 5% CO2. EC17,
HEK293T, HeLa and MCF-7 cells were maintained in DMEM
supplemented with 10% FBS, 100 U/mL penicillin G, and
0.1 mg/mL kanamycin in the same conditions described above.
The other cells were maintained in RPMI-1640 medium supple-
mented with 10% FBS, 100 U/mL penicillin G and 0.1 mg/mL
kanamycin, also in the abovementioned conditions.
Cell cycle and apoptosis analysis by flow cytometry. The per-
centage of cells in different phases of the cell cycle, including
the sub-G1 population, was analyzed by flow cytometry fol-
lowing staining with propidium iodide (PI; Wako Pure Chemi-
cal Industries). In brief, cells were seeded in 6-well plates and,
following overnight culture, were treated with XN for 48 h. In
the co-treatment test for the PKA inhibitor and XN, the cells
were pre-treated with PKA inhibitor for 1 h before being trea-
ted with XN. Following treatment, cells were harvested and
fixed with ice-cold 70% EtOH at 4°C, followed by treatment
with 10 lg/mL RNase A (Wako Pure Chemical Industries) for
20 min at 37°C. Subsequently, cells were stained with 50 lg/
mL PI. PI fluorescence was measured by EPICS ALTRA
(Beckman Coulter, Brea, CA, USA).
To illustrate a waterfall plot, Z-score values were calculated
using EC50 values of each cell viability (Xi), its mean (Xmean)
and its standard derivation (S) using the following formula:
Z  score ¼ ðXmean  XiÞ=S
Western blot analysis. Anti-cleaved-PARP, anti-VCP and
anti-survivin were purchased from Cell Signaling Technology
(Danvers, MA, USA). Anti-b-actin, HRP-linked anti-mouse
IgG and HRP-linked anti-rabbit IgG were purchased from
Sigma-Aldrich. Cells were immediately harvested and lysed
with RIPA buffer (25 mM HEPES, 1.5% TX-100, 1% sodium
deoxycholate, 0.1% SDS, 500 mM NaCl, 5 mM EDTA,
50 mM NaF, 0.1 M Na3VO4 and cOmplete Protease Inhibitor
Cocktail Tablets [Roche, Mannheim, Germany]; pH 7.8). The
lysates were centrifuged at 13 000 g for 15 min to remove the
insoluble fraction. Equal amounts of total protein were subse-
quently separated by SDS-polyacrylamide gel electrophoresis
before being transferred onto a PVDF membrane (Millipore,
Billerica, MA, USA). The membrane was probed with the
indicated antibodies. The chemiluminescence signal was
detected using an Immobilon Western kit (Millipore) and Che-
miDoc XRS+ System (Bio-Rad, Hercules, CA, USA).
Anti-tumor efficacy in the xenograft model. Six-week old
female BALB/c nude mice were purchased from Charles River
Laboratories (Tokyo, Japan). XN was suspended in DMSO at
a concentration of 100 mM, then diluted with PBS to the con-
centrations indicated and given daily to the mice. Conversely,
control mice received a vehicle control of 0.85% DMSO corre-
sponding to 30 mg/kg XN. Each suspension (1 9 107 cells/
mouse) of HCT116 and SW480 cells was mixed with an equal
volume of Matrigel (BD, Franklin Lakes, NJ, USA) and
injected subcutaneously into the left flank of mice. After the
tumors developed over a period of 1 week, reaching sizes of
approximately 150 mm3 (calculated as 1/2 9 [width 9
length2]), mice were randomized into four groups of five and
administered drugs by intraperitoneal injection for 17 days.
Tumor volume was measured with callipers. Thereafter, mice
were killed and tumors were dissected; images were captured
with a digital camera.
After being killed, the organs (heart, lung, liver, kidney,
spleen and pancreas) were removed immediately. A portion of
each tissue was fixed in 10% neutral formalin for histological
examination, while the remaining tissue sample was frozen,
and preserved at 80°C for subsequent immunohistochemistry.
All experiments were performed in accordance with the guide-
lines of the animal facility at Tokushima University.
Immunohistochemical staining of xenografts. Anti-Ki67 anti-
body [Sp6], (ab16667) was purchased from Abcam (Cam-
bridge, USA).
Anti-rabbit immunoglobulins/HRP antibody (P0448) and Liq-
uid DAB+ (K3468) were purchased from DAKO (Carpinteria,
CA, USA). To examine the Ki67 protein expression in HCT116
xenograft tumors, we stained the tissue sections of paraffin-
embedded tumors. In brief, 4-lm sections were dewaxed in
xylene and ethanol. The slides were subjected to high-tempera-
ture antigen retrieval in citric buffer (10 mM, pH 6.0). After
antigen retrieval, the slides were dipped in methanol containing
H2O2 [0.3% (v/v)] for 30 min. After washing with 10 mM PBS
at pH 7.4, the slides were incubated with anti-Ki67 (dilution
1:1600) antibody with microwave irradiation. The slides were
then washed with PBS three times for 5 min each time; anti-
rabbit immunoglobulins/HRP antibody was applied to the
slides. After washing with PBS three times, the expression of
Ki67 was visualized as brown precipitates with liquid DAB+.
After washing with distilled water, nuclear counterstaining was
performed with hematoxylin. The nuclear labeling index of the
Ki67 staining was determined under microscope (BX-50, Olym-
pus, Tokyo, Japan) for regular pathological diagnosis. In brief,
1000 tumor cells were counted manually and the positive ratio
was calculated in each xenograft. Statistical analysis was per-
formed by Graphpad prism 5 (GraphPad Software, La Jolla,
CA, USA).(21).
Lentiviral genome-wide shRNA screening. A dose response
curve of XN for HCT116 was calculated using xCelligence
(ACEA Biosciences, San Diego, CA, USA), an automated cell
growth analyzer. HCT116 cells were cultured at a variety of
XN concentrations for 48 h and the real-time cell growth rates
were recorded by the xCELLigence.
Genome-wide lentiviral shRNA screenings were performed
using HCT116 cells. In brief, an shRNA lentivirus library con-
taining approximately 27 500 barcoded shRNA (DECIPHER
shRNA Library: Human Module #1, Cellecta, Mountain View,
CA, USA) was produced according to the manufacturer’s pro-
tocol, after which 2.0 9 107 HCT116 cells were infected by
the lentivirus and maintained for 48 h after infection. The
shRNA lentivirus-infected HCT116 cells were then selected by
puromycin (1.0 lg/mL) for 72 h; the selected cells were then
separated into two 15-cm culture dishes with an equal number
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of cells, one of which contained XN at a 7.0 lM concentration
and the other cultured with DMSO as a control. At 72 h after
the XN treatment, the HCT116 cells were harvested and their
genomic DNA extracted using a QiaAmp DNA Mini Kit (Qia-
gen, Hilden, Germany). The shRNA-specific barcode regions
were then amplified by PCR according to the manufacturer’s
protocol, with mild modifications for the PCR primers to make
the PCR amplicons readable by an Ion PGM System (Thermo
Scientific, Waltham, MA, USA). Quantifications of the cellular
clone sizes of each shRNA-infected HCT116 population within
control or XN-treated culture conditions were calculated based
on the sequence read counts within each sample. shRNA that
suppress growth of infected cells in synergy with XN should
show significant decreases in the sequence read counts specifi-
cally under the XN condition. Therefore, genes that exhibited
more than fivefold high frequencies in DMSO-treated cells
compared to the XN-treated cells were selected as “hit genes.”
Thereafter, Gene Ontology-based bioinformatics analysis was
performed for the hit genes using the DAVID bioinformatics
database focusing on molecular functions and biological
processes.(22,23).
Growth inhibition assay and isobologram test. Cell growth
was measured by using an MTT assay. In brief, cells were
seeded in 96-well plates and, after overnight culture, were trea-
ted with H-89 or KT5720 for 1 h. Thereafter, cells were trea-
ted with XN, ESI or PTX for an additional 72 h. Following
treatment, cells were treated with 0.5 mg/mL MTT (Sigma-
Aldrich) for 4 h at 37°C, and lysed with DMSO. Absorbance
at 595 nm was measured by a Multiskan FC (Thermo Scien-
tific) and IC50 values of each combination of two agents were
calculated and plotted on the graph.
For each combination experiment, the combination indexes
(CI) were calculated and normalized with IC50 values as
reported(24) and plotted on an isobologram graph.(25) On the
isobologram, a straight line connecting the x-intercepts and
y-intercepts and the intervening points infers an additive effect
between two agents. Conversely, a concave or convex line
infers a synergism or an antagonism between the two agents,
respectively.
Results
Xanthohumol exhibited antitumor activity in vitro and
in vivo. First, we examined the effect of XN on 18 different
human tumor cell lines chosen in a random manner. Each cell
was treated with XN for 48 h and the sub-G1 populations were
determined via flow cytometry. Z-score values were then calcu-
lated using EC50 values of cell viability and plotted on a water-
fall plot. As shown in Figure 1(a), seven cell lines, including
SW480, SW48, DLD-1, SW620, A2058, LS-174T and HCT116
cells, were highly sensitive to XN. However, there were not
significant differences in VCP expression levels between XN-
sensitive cells and the other cell lines (Fig. 1b). Subsequently,
we detected the expression levels of cleaved-PARP by western
blot to confirm the apoptosis-inducing ability of XN. As shown
in Figure 1(c), when XN-sensitive SW480 and HCT116 cells
and XN-insensitive HT29 and A549 cells were treated with
indicated concentrations of XN for 24 h, the expression levels
of cleaved-PARP increased in XN-sensitive SW480 and
HCT116 cells, but not in HT29 and A549 cells. We correlated
these results with a waterfall plot analysis.
We next investigated the antitumor effects of XN against XN-
sensitive cells in vivo. Human colorectal tumor HCT116 and
SW480 cells were injected subcutaneously into nude mice to
establish xenograft models. Mice were randomized into four
groups of five, after which the vehicle or XN was administered
by intraperitoneal injection. As shown in Figure 1(d,e), tumor
growth inhibition was observed in each xenograft model in a
dose-dependent manner, without significant body weight loss
(Fig. 1f). Furthermore, we evaluated its effect on Ki67 labeling
index as a tumor proliferative index using immunohistochemical
(IHC) methods. A significant reduction of Ki67 labeling index
in tumors was observed in dose-dependent manner (Fig. 1g).
These results indicated that XN exhibited antitumor activity
against several human tumor cell lines in vitro and in vivo.
shRNA screening reveals the adenylate cyclase pathway is cor-
related with xanthohumol-induced cell death. To identify the
key genes playing a critical role in XN-induced cell death, we
generated a lentiviral-based shRNA screening system and
screened for genes related to the antitumor activity of XN
using HCT116 cells. Before the screening, we determined the
drug concentration to be somewhat lower than the IC50 value
because at the concentration of IC50, the shRNA-infected cells
exhibit too many “random deaths” due only to the drug func-
tion without the synthetic shRNA effects. In our study, to
decide on the concentration of XN for the shRNA screening,
we performed a growth inhibition assay and the IC50 value
was calculated. A dose response curve of XN for HCT116 is
shown in Figure S1, and the IC50 value was approximately
8.1 lM. Then, we decided to conduct the shRNA screening at
the concentration of 7.0 lM XN, at a lower concentration
compared to the IC50, based on the abovementioned theoretical
background.
Next, HCT116 cells were infected with a mixture of approxi-
mately 27 500 barcoded shRNA and cultured in the presence of
either 7.0 lM XN or DMSO. After 3 days, genomic DNA was
isolated from the cells and the shRNA-specific barcode regions
were amplified by PCR with the lentivirus vector-specific pri-
mers. The abundance of each shRNA was then quantified by
high-throughput sequencing (Fig. 2). As a result, 138 shRNA,
which exhibited more than fivefold high frequencies in DMSO-
treated cells compared to XN treated cells, were selected as the
hit genes (Table S1). This suggests that knockdown of these
genes enhances the antitumor activity of XN, because HCT116
cells infected with these 138 shRNA showed growth inhibition
specifically under the synergic XN culture condition. Subse-
quently, Gene Ontology-based bioinformatics analysis was per-
formed on the hits using the DAVID bioinformatics
database.(22,23) As a result, Gene Ontology-term enrichment
analysis of the hit genes, focusing on molecular functions and
biological processes, showed strong enrichment of genes
involved in adenylate cyclase activity (Tables S2 and S3). These
results raised the possibility that the adenylate cyclase pathway
may play a crucial role in XN-induced cell death.
Protein kinase A inhibitors enhanced the antitumor activity of
valosin-containing protein inhibitors. The Adenylate cyclase
(AC) pathway, also known as the cyclic AMP (cAMP)-depen-
dent pathway, is a well-known G protein-coupled receptor-
regulated signaling cascade. The G protein families, including
Gi and Gs, regulate AC activity. AC catalyzes the conversion
of ATP to cAMP, which, in turn, regulates cellular function
via activating protein kinase A (PKA)-dependent phosphoryla-
tion.(20) Therefore, to examine whether the suppression of the
AC/PKA pathway could synergistically enhance the antitumor
activity of XN, we performed an MTT assay using the PKA
inhibitor H-89(26) and graphically plotted the results on
isobolograms.(24,25) HCT116 cells were treated with various
concentrations of XN in the presence or absence of H-89 for
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72 h and cell viability was measured by MTT assay. IC50 val-
ues of each combination of two agents and the combination
indexes (CI) were then calculated and plotted on an isobolo-
gram. The combination of H-89 with XN produced a concave
line, indicating a synergistic interaction (Fig. 3a). Similar
results were obtained when another PKA inhibitor, KT5720,(27)
was used instead of H-89 (Fig. 3b). Conversely, when using
the non-specific cytotoxic agent paclitaxel (PTX) instead of
XN, H-89 plus PTX produced a straight line, indicating an
additive interaction in the HCT116 cells (Fig. 3c). Thus, PKA
inhibition is responsible for synergistically enhancing the anti-
tumor activity of XN. We then performed similar tests using
another VCP inhibitor, eeyarestatin I (ESI).(28) As shown in
Figure 3(d), the combinations of H-89 with ESI produced a
concave line, indicating a synergistic interaction in HCT116
cells. Furthermore, the synergistic effect of H-89 and XN was
confirmed in the other human tumor cell lines, XN-sensitive
SW480 and XN-insensitive HT29 cells (Fig. 3e,f). These
results suggest that the inhibition of AC/PKA pathway syner-
gistically enhances the antitumor activity of VCP inhibitors,
including XN and ESI, in various types of human tumor cell
lines.
Synergistic effect of protein kinase A inhibition and xanthohu-
mol on apoptosis induction. We next investigated whether the
combination of PKA inhibitors with XN exhibited a synergistic
interaction on apoptosis induction. HCT116 cells were treated
with the indicated concentrations of XN in the presence or
absence of 10 lM H-89 or KT5720 for 48 h, after which sub-
G1 populations were measured by PI-stain and flow cytometry.
As shown in Figure 4(a,b), co-treatment of PKA inhibitors and
XN synergistically increased sub-G1 populations compared to
XN alone, indicating that PKA inhibitors affected the apopto-
sis-inducing activity of XN. Interestingly, XN or H-89 alone
did not increase the sub-G1 population in HT29, A549 and
LoVo cells. However, combinations with H-89 could increase
the sub-G1 population in these cell lines, indicating that H-89
treatment might facilitate XN-induced apoptosis also in XN-in-
sensitive cells (Fig. 4c–e).
Discussion
Xanthohumol, a simple prenylated chalcone, is the most well
studied compound isolated from hops because of its potential
as a cancer chemopreventive agent against several human
tumor cell lines.(29–31) Therefore, many researchers have pro-
posed various molecular mechanisms explaining how XN exhi-
bits antitumor activity. However, until now, there have been
no reports of the contribution of valosin-containing protein
(VCP) inhibition to XN’s antitumor activity. VCP may play
crucial roles in cancer progression, prognosis and recur-
rence,(17–19) and we previously reported that XN directly binds
to VCP and inhibits its functions.(11) Therefore, in the current
work, we examined the antitumor activity of XN targeting
VCP.
We first investigated which human tumor cell lines were
sensitive to XN, revealing several cell lines highly sensitive to
XN in vitro. Overexpression of VCP occurs in many cancers
and clinical studies have reported a correlation between ele-
vated VCP expression and its progression.(32) However,
because significant differences in the expression levels of VCP
were not found among the cell lines we tested, XN sensitivity
is not dependent on VCP expression levels. Conversely,
another VCP inhibitor, eeyarestatin I (ESI), showed antitumor
effects in tumor cells with a similar waterfall profile to XN
(Fig. S2), indicating that inhibition of VCP function is respon-
sible for cell viability in XN-sensitive tumor cells. VCP func-
tions as a critical mediator of protein homeostasis. VCP is
essential to some aspects of ubiquitin-dependent proteasomal
degradation, including endoplasmic reticulum-associated degra-
dation (ERAD), which degrades misfolded proteins. VCP is
also involved in the aggresome–autophagy pathway, which is
required for clearing misfolded proteins that form aggregates
in the cytosol. The malignant transformation may result in cell
deregulation often associated with cellular stress, such as accu-
mulation of misfolded proteins; adaptation to this stress pheno-
type is required for tumor cells to survive. Therefore, although
the detailed function of VCP in XN-sensitive tumor cells
remains unclear, subsets of tumor cells (XN-sensitive tumor
cells) may, in turn, depend on VCP function.
Fig. 2. shRNA screening for the identifications of key factors modu-
lating antitumor activity of xanthohumol. A lentiviral-based shRNA
screening was performed for screening genes related to the antitumor
activity of xanthohumol (XN). HCT116 cells were infected with an
shRNA lentivirus library containing approximately 27 500 shRNA and
then cultured in the presence or absence of 7.0 lM XN for 3 days.
Genomic DNA was isolated and amplified by PCR targeting
shRNA-specific barcode regions. Each shRNA was then quantified by
high-throughput sequencing. The x-axis and y-axis represent clone
frequency of each shRNA from the cells cultured with DMSO and XN,
respectively. The hit genes that exhibited more than fivefold high
frequencies in DMSO-treated cells compared to the XN-treated cells
are represented by black dots.
Fig. 1. Antitumor activities of xanthohumol in vitro and in vivo. The effects of xanthohumol (XN) on several types of human tumor cell lines
and xenograft models were examined. (a) The sub-G1 populations were determined 48 h after XN treatment via flow cytometry. Z-score values
were calculated as described in the Materials and Methods and plotted on a waterfall plot. (b) The expression levels of valosin-containing pro-
tein (VCP) in several human tumor cells were detected by western blot. (c) XN-sensitive SW480 and HCT116 cells and XN-insensitive HT29 and
A549 cells were treated with XN for 24 h and the expression levels of cleaved-PARP were detected by western blot. (d–f) Human colorectal
tumor HCT116 and SW480 cells, the XN-sensitive cells, were injected subcutaneously into nude mice to establish xenograft models. After the
tumors developed over a period of 1 week, reaching sizes of approximately 150 mm3, mice were randomized into four groups of five, after
which the vehicle or XN was administered daily by intraperitoneal injection for 17 days. Tumor size and body weight were measured and tumors
were dissected and imaged with a digital camera. (g) Dose-dependent inhibition of Ki67 labeling index by XN treatment in tumor xenografts
in vivo. Nuclear Ki67 labeling index at indicated dose levels was determined in HCT116 tumors on study day 17.
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Previously, Yoshimaru et al. report that XN treatment (0.3–
1.0 mg/kg) significantly inhibited estrogen (E2)-induced tumor
growth through specific disruption of the BIG3–PHB2 interac-
tion, regardless of VCP function in vivo.(10) Conversely, the
lower dose range of XN did not show significant antitumor
effects on the human colorectal tumor HCT116 and SW480
cells in vivo, but significant tumor growth inhibition was
observed in these cells in response to daily intraperitoneal
injection of higher doses of XN (15–30 mg/kg), possibly
through VCP inhibition. Notably, no morphological changes
were observed in the heart, lung, liver, kidney, spleen and pan-
creas of mice, despite receiving high doses of XN (30 mg/kg)
daily for 17 days (Fig. S3). However, what determines the sen-
sitivity to XN remained elusive. When we compared the effect
of XN on the expression levels of several pro-apoptosis and
anti-apoptosis proteins in XN-sensitive cells, only expression
levels of survivin were found to be affected by XN. XN
induced a decrease in the expression levels of survivin in XN-
sensitive cells (HCT116 and SW480 cells) in a dose-dependent
manner; however, XN weakly suppressed the expression levels
of survivin in XN-insensitive tumor cells (A549 and HT29
cells), as shown in Figure S4. Therefore, it is likely that the
effect of XN on survivin expression may be related to the sen-
sitivity of tumor cells to XN.
We also determined which key factors modulate the apopto-
sis-inducing activity of XN. For this, we performed shRNA
screening and bioinformatics analysis. Interestingly, the adeny-
late cyclase (AC) pathway-related genes were hits, indicating
that the AC pathway plays a crucial role in XN-inducing apopto-
sis. The AC pathway is known to activate protein kinase A
(PKA) phosphorylation via converting ATP to cyclic AMP
(cAMP) and regulating target genes.(20) We found in this study
that in the tumor cell lines we tested, the inhibition of PKA, a
downstream kinase of AC and cAMP, enhanced the apoptosis-
inducing activity of XN. These results raised the possibility that
the AC/PKA pathway could contribute to preventing apoptosis
induced by VCP inhibition and that the activity of AC/PKA
pathway in tumor cells could determine sensitivity to XN.
Fig. 3. Combination experiment of protein kinase A and valosin-containing protein inhibition. To investigate the combination efficacy between
protein kinase A (PKA) and valosin-containing protein (VCP) inhibition, an MTT assay was performed and the isobologram was plotted. (a,b)
HCT116 cells were treated with various concentrations of xanthohumol (XN) in the presence or absence of H-89 or KT5720 for 72 h and the cell
viability was measured by MTT assay. The combination index (CI) for each combination of two agents was calculated using the IC50 value and
plotted on the isobologram, as described in the Materials and Methods. (c) Paclitaxel, a non-specific cytotoxic agent as a negative control, was
used instead of XN in HCT116 cells. As described above, CI was calculated and the isobologram was plotted. (d) Eeyarestatin I, another VCP inhi-
bitor, was used instead of XN in HCT116 cells. As described above, CI was calculated and the isobologram was plotted. (e,f) The synergistic effect
of H-89 and XN was confirmed in the other human tumor cell lines, XN-sensitive SW480 and XN-insensitive HT29 cells. Each cell was treated with
various concentrations of XN in the presence or absence of H-89 for 72 h and the isobologram was plotted.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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Fig. 4. The combination efficacy of protein kinase A inhibition and xanthohumol on apoptosis induction. The sub-G1 population was measured
via flow cytometry to investigate whether the combination of protein kinase A (PKA) inhibitor with xanthohumol (XN) exhibits the synergistic
interaction on apoptosis induction. (a,b) HCT116 cells were treated with various concentrations of XN in the presence or absence of H-89 or
KT5720 for 48 h and the sub-G1 populations were measured via flow cytometry. (c–e) The synergistic effect of H-89 and XN was confirmed in the
other human tumor cell lines, XN-insensitive HT29, A549 and LoVo cells. Cells were treated with various concentrations of XN in the presence or
absence of H-89 for 48 h and the sub-G1 populations were measured as described above.
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Fig. 4. continued.
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Recently, it has been reported that XN acts at GABAA receptors
present in the hippocampal nerve terminals to decrease the Ca2+
influx through N-type and P/Q-type Ca2+ channels, which subse-
quently suppresses the Ca2+-calmodulin/PKA cascade to
decrease the evoked glutamate release.(33) These results indi-
cated that XN-mediated decrease in the Ca2+ influx caused the
suppression of the PKA cascade in the rat hippocampus, and,
therefore, H-89 has been shown to largely prevent the inhibition
of glutamate release by XN. In contrast, we found that H-89 did
not prevent apoptosis by XN; rather, it synergistically enhanced
the antitumor activity of XN. Therefore, XN did not induce the
suppression of PKA in tumor cells, and the target of XN to
induce apoptosis was different from that of PKA inhibitors.
The next question was how the AC/PKA pathway prevented
apoptosis signals induced by VCP inhibition. Several previous
studies have reported the anti-apoptotic role of AC/PKA in
various types of cells; however, the mechanisms through which
PKA works are often not known. One well-described anti-
apoptotic role of PKA is that PKA inhibition induces a
decrease in expression levels of survivin, an anti-apoptotic pro-
tein, in human colorectal tumor SW480 cells.(34) We also
found that H-89 at 10 lM suppressed the expression levels of
survivin in XN-sensitive and XN-insensitive tumor cells. In
addition, suppressed expression of survivin by H-89 was fur-
ther enhanced in the presence of XN (Fig. S4). Therefore,
decreased expression of survivin by both PKA inhibition and
VCP inhibition may be responsible for the synergistic enhance-
ment of apoptosis by VCP inhibition and PKA inhibition. Fur-
ther studies will be necessary to exactly delineate the factors
contributing to the suppression of survivin expression by XN
or PKA inhibitor.
In conclusion, our findings suggest that several human tumor
cell lines require VCP function for their survival, and that tar-
geting both VCP and the AC/PKA pathway is a potential
chemotherapeutic strategy for the subset of tumor cells.
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